TNFSF11 and cancer: Recently, it was demonstrated that tumor-derived RANKL in cancer-bearing mice is associated with increased bone turnover and skeletal muscle atrophy, while anti-RANKL or bisphosphonate treatment preserved bone and partially prevented the loss of muscle mass and strength [212••].